Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | TLR4 | O00206 | 1/20 | 0.56 |
| ▸ | DPP4 | P27487 | 6/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.55 |
| ▸ | CPB1 | P15086 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21198114 | 1.00 | TSHR (0.67) | TSHRALDH1A1GAAEPHX1TLR4 | |
| SCHEMBL14981586 | 1.00 | TSHR (0.67) | TSHRALDH1A1GAAEPHX1TLR4 | |
| Hydrochloric Acid SCHEMBL16430999 | 0.99 | TSHR (0.66) | TSHRALDH1A1GAAEPHX1TLR4 | |
| SCHEMBL2124491 | 0.92 | TSHR (0.61) | TSHRALDH1A1GAAEPHX1TLR4 | |
| SCHEMBL16523975 | 0.92 | TSHR (0.61) | TSHRALDH1A1GAAEPHX1TLR4 | |
| SCHEMBL16070788 | 0.92 | TSHR (0.61) | TSHRALDH1A1GAAEPHX1TLR4 | |
| SCHEMBL2124493 | 0.92 | TSHR (0.61) | TSHRALDH1A1GAAEPHX1TLR4 | |
| SCHEMBL6371177 | 0.92 | TSHR (0.61) | TSHRALDH1A1GAAEPHX1TLR4 | |
| SCHEMBL1192792 | 0.92 | TSHR (0.75) | TSHRALDH1A1GAAEPHX1TLR4 | |
| SCHEMBL880579 | 0.92 | TSHR (0.75) | TSHRALDH1A1GAAEPHX1TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024506-B2 | Compounds | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-02 | — | — | US | disclosed |
| EP-3743421-B1 | COMPOUNDS | UNIV OXFORD INNOVATION LTD (GB) | 2023-03-29 | — | — | EP | disclosed |
| US-20210009576-A1 | COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-01-14 | — | — | US | disclosed |
| EP-3743421-A1 | COMPOUNDS | Oxford University Innovation Limited (GB) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019145718-A1 | COMPOUNDS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-08-01 | — | — | WO | disclosed |
| US-5925624-A | ANTIINFLAMMATORY AGENTS TREATING PATIENTS WITH INFLAMMATORY CONDITIONS SUSCEPTIBLE TO LEUKOCYTE-INDUCED TISSUE DAMAGE | GLAXO GROUP LIMITED (GB) | 1999-07-20 | — | — | US | disclosed |
| US-5889178-A | N-(2,2-DIPHENYLETHYL)-DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-03-30 | — | — | US | disclosed |
| EP-0680488-A1 | 2,6-DIAMINOPURINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1995-11-08 | — | — | EP | disclosed |
| WO-1994017090-A1 | 2,6-DIAMINOPURINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1994-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009576-A1 | COMPOUNDS | KRAS, NRAS, HRAS | TSHR 4071/4885ALDH1A1 3190/4885GAA 1808/4885 |
| US-12024506-B2 | Compounds | KRAS, NRAS, HRAS | TSHR 4071/4885ALDH1A1 3190/4885GAA 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.